Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis.

ABSTRACT:

Background

One in 7 adults have chronic kidney disease (CKD), which is associated with high morbidity and mortality and substantial health care costs, especially in more advanced disease. Our data from a US commercial payer show rising per-member-per-year costs for renal and cardiac complications associated with CKD.

Objective

To predict the clinical and economic impact of treatment with or without dapagliflozin from the perspective of a US commercial payer using a cost-offset model (COM).

Methods

The COM used real-world cost and member count data from a US employer-sponsored commercial payer and results of the double-blind, randomized, phase 3 Dapagliflozin and Prevention of Adverse Outcomes in CKD clinical trial (NCT03036150) to predict the incidence of clinical eve

SUBMITTER: Chang RC 

PROVIDER: S-EPMC11293758 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature